SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nationâs largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2025.
Related Questions
What is the current guidance for FY2025 (revenue, EPS, margins) and how does it compare to consensus forecasts and peer performance?
Did the company provide guidance for Q3 and fullâyear 2025, and how does it compare to its prior guidance and consensus forecasts?
Were there any management or board changes announced that could impact strategic direction?
How did operating margins, EBITDA, and costâstructure metrics compare to expectations and prior periods?
How did LifeStance's Q2 revenue compare to the prior-year quarter and consensus estimates?
Are there any regulatory, reimbursement, or policy developments highlighted that could materially affect the business outlook?
Did LifeStance report any significant acquisitions, divestitures, partnerships, or strategic initiatives in the quarter?
What were the cash flow results (operating cash flow, free cash flow) and any notable changes in the balance sheet (cash, debt, capital expenditures)?
What were the key takeâaways from the earnings call (management commentary, outlook, risk factors) that may influence future performance?
What was the reported adjusted EPS for the quarter and how does it stack up against analyst forecasts?
How did the market react on the day of the release (price movement, volume, beta) and what technical signals does the price action suggest?
How does LifeStance's valuation metrics (P/E, EV/EBITDA, priceâtoâsales) compare to its main competitors in the outpatient mentalâhealth space?
What were the primary drivers of revenue growth or decline (e.g., patient volume, reimbursement rates, new clinic openings, or closures)?